GlassScriptPhysician profile
Jane Paino
NPI 1497837363
$9,938.14
in general payments reported to CMS, 2019-2025
47 companies · $2,183 in 2025
The $2,183 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,527 · 2020: $876 · 2021: $58.37 · 2022: $1,316 · 2023: $1,837 · 2024: $2,140 · 2025: $2,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,160.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,283.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,184.58 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $808.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $776.21 | 2019-2025 | |
| Amgen INC. | $716.57 | 2019-2025 | Repatha, Otezla, Tepezza |
| Corcept Therapeutics | $694.08 | 2023-2025 | Korlym |
| Pfizer INC. | $673.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $626.11 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $286.57 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $280.76 | 2023-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $239.20 | 2020-2024 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $226.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $211.38 | 2019-2025 | |
| Allergan, INC. | $199.96 | 2019 | |
| Astellas Pharma US INC | $191.62 | 2019-2025 | Veozah |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $149.86 | 2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.69 | 2022-2024 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $120.84 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $113.58 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $92.83 | 2019 | |
| Relievant Medsystems, INC. | $86.67 | 2022 | |
| Recordati_rare_diseases_inc. | $83.63 | 2025 | Isturisa |
| Radius Health, INC. | $83.30 | 2023-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.55 | 2019-2023 | Xifaxan |
| Abbott Laboratories | $63.28 | 2023-2025 | Freestyle Libre 2, Aveir |
| Merck Sharp & Dohme LLC | $50.86 | 2022-2025 | Capvaxive |
| Tandem Diabetes Care, INC. | $44.61 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Exact Sciences Corporation | $43.55 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $38.86 | 2019 | |
| Almatica Pharma LLC | $35.87 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Daiichi Sankyo INC. | $29.25 | 2024 | Injectafer |
| Mylan Specialty L.P. | $27.47 | 2023-2024 | Yupelri |
| Nalpropion Pharmaceuticals LLC | $23.58 | 2019 | |
| Sanofi Pasteur INC. | $23.28 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.45 | 2025 | Caplyta |
| Mannkind Corporation | $22.43 | 2025 | |
| Chiesi USA, INC. | $22.42 | 2025 | Mycapssa |
| Kyowa Kirin, INC. | $21.66 | 2023 | Crysvita |
| Beta Bionics, INC. | $19.93 | 2023 | Ilet Bionic Pancreas |
| Bayer Healthcare Pharmaceuticals INC. | $18.60 | 2023 | |
| Dexcom, INC. | $17.13 | 2025 | Dexcom G6 Transmitter |
| Shire North American Group INC | $16.73 | 2019 | |
| Circassia INC. | $16.16 | 2019 | |
| Aimmune Therapeutics, INC. | $15.54 | 2025 | Zenpep |
| Amneal Pharmaceuticals LLC | $15.34 | 2023 | Unithroid |
| Biohaven Pharmaceutical Holding Company LTD. | $14.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Paino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.